CANDESARTAN CILEXETIL
Clinical safety rating: avoid
Contraindicated (not allowed)
Candesartan cilexetil is a prodrug that is hydrolyzed to candesartan, an angiotensin II receptor blocker (ARB) that selectively and competitively binds to the angiotensin II type 1 (AT1) receptor, blocking the vasoconstrictor and aldosterone-secreting effects of angiotensin II. This results in decreased peripheral resistance and blood pressure.
| Metabolism | Candesartan cilexetil is rapidly and completely hydrolyzed during gastrointestinal absorption to the active metabolite candesartan. Candesartan is further metabolized in the liver via O-deethylation to an inactive metabolite. CYP2C9 is the primary enzyme involved, with minor contribution from CYP3A4. |
| Excretion | Candesartan is eliminated primarily via the kidneys (approximately 60% of recovered dose) and the feces (approximately 40%) following biliary excretion. Less than 1% is excreted unchanged in urine. |
| Half-life | The terminal elimination half-life is approximately 9 hours. In clinical practice, this supports once-daily dosing, with steady state achieved within 3–4 days. |
| Protein binding | Candesartan is highly protein bound (>99%), primarily to albumin. |
| Volume of Distribution | The volume of distribution is approximately 0.13 L/kg, indicating extensive distribution into tissues. |
| Bioavailability | Absolute oral bioavailability of candesartan cilexetil is approximately 15% (range 5–20%), due to incomplete absorption and extensive first-pass metabolism to the active candesartan. |
| Onset of Action | Oral: Onset of antihypertensive effect is within 2–4 hours after a single dose, with maximal effect observed at 4–8 hours. |
| Duration of Action | The antihypertensive effect persists for 24 hours after a single oral dose, allowing once-daily administration. The trough-to-peak ratio is >80%, indicating sustained 24-hour efficacy. |
Oral, 8 mg once daily initially, titrate to 16-32 mg once daily as tolerated; maximum 32 mg/day.
| Dosage form | TABLET |
| Renal impairment | GFR 15-29 mL/min/1.73m²: starting dose 4 mg once daily; GFR <15 mL/min or on hemodialysis: not recommended. |
| Liver impairment | Child-Pugh A or B: no adjustment necessary; Child-Pugh C: not studied, use with caution. |
| Pediatric use | Weight <50 kg: 4-16 mg once daily; Weight ≥50 kg: 8-32 mg once daily; starting dose 4 mg once daily for all. |
| Geriatric use | Initial dose 4 mg once daily due to potential renal impairment; titrate based on response and tolerability; monitor serum potassium and creatinine. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
NSAIDs may diminish the antihypertensive effect Lithium levels may be increased Use in pregnancy can cause injury and death to the developing fetus.
| Breastfeeding | Excreted in human milk in low amounts; M/P ratio unknown. Due to potential adverse effects on neonatal renal function, use while breastfeeding is not recommended, particularly in preterm or neonates with compromised renal function. |
| Teratogenic Risk | First trimester: Data limited, but potential risk of minor malformations. Second and third trimesters: Known to cause fetal renal dysfunction, oligohydramnios, skull ossification defects, and neonatal anuria/renal failure. Contraindicated in pregnancy, especially after 20 weeks gestation. |
■ FDA Black Box Warning
When pregnancy is detected, discontinue candesartan as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
| Common Effects | heart failure |
| Serious Effects |
["Hypersensitivity to candesartan or any component of the formulation","Pregnancy (C-I category in second and third trimesters)","Concomitant use with aliskiren in patients with diabetes mellitus"]
| Precautions | ["Fetal toxicity: Discontinue if pregnancy is detected.","Hypotension in volume- or salt-depleted patients (e.g., those treated with diuretics).","Monitor renal function; may cause acute renal failure, especially in patients with renal artery stenosis, advanced heart failure, or volume depletion.","Hyperkalemia: More common in patients with renal impairment, diabetes, or on potassium-sparing diuretics/supplements.","Angioedema: Rare but may occur; discontinue immediately if suspected."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, renal function (serum creatinine, BUN), and electrolytes. Fetal monitoring includes ultrasound for amniotic fluid volume and fetal growth. If exposed after 20 weeks, monitor for oligohydramnios and neonatal renal function. |
| Fertility Effects | No significant adverse effects on fertility have been reported in animal studies. Human data are limited; however, angiotensin receptor blockers may theoretically impact fertility by altering renal and vascular hemodynamics. |
| Food/Dietary |
| Avoid potassium-containing salt substitutes and high-potassium foods (e.g., bananas, oranges, avocados, spinach) unless directed by a healthcare provider, as candesartan may increase serum potassium. No significant food effect on absorption; can be taken with or without food. |
| Clinical Pearls | Candesartan cilexetil is a prodrug that is hydrolyzed to active candesartan during absorption. It has a long half-life allowing once-daily dosing. Monitor renal function and electrolytes, especially in patients with renal artery stenosis, heart failure, or on concurrent NSAIDs. Avoid use in pregnancy, particularly during second and third trimesters. May cause symptomatic hypotension in volume-depleted patients. |
| Patient Advice | Take once daily with or without food, preferably at the same time each day. · Do not use if pregnant or planning pregnancy; seek alternative antihypertensive if applicable. · May cause dizziness or lightheadedness; avoid driving until you know how the medication affects you. · Do not use salt substitutes containing potassium without consulting your doctor. · Report symptoms of angioedema (swelling of face, lips, tongue, or throat) immediately. · Stay hydrated, but avoid excessive dehydration (e.g., from diarrhea, vomiting) as it may increase side effects. |